Larimar Therapeutics (LRMR) Amortizatization of Intangibles (2015 - 2025)
Larimar Therapeutics' (LRMR) quarterly Amortizatization of Intangibles came in at -$157000.0 in Q4 2025, up 86.72% on a YoY basis from -$84084.3 in Q4 2024, and up 51.69% quarter-over-quarter from -$325000.0 in Q3 2025.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Amortizatization of Intangibles (2015 - 2025) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Amortizatization of Intangibles for 9 consecutive years, with -$157000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Amortizatization of Intangibles rose 86.72% year-over-year to -$157000.0; the trailing twelve-month figure through Dec 2025 stood at -$1.7 million (up 67.69% YoY), and the FY2025 full-year result was -$1.7 million, up 67.69% from the prior year.
- Amortizatization of Intangibles improved to -$157000.0 in Q4 2025 per LRMR's latest filing, from -$325000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $3.1 million in Q4 2023 and bottomed at -$1.8 million in Q2 2024.
- Historically, Amortizatization of Intangibles has averaged -$327555.6 across 5 years, with a median of -$393000.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles tumbled 35300.0% in 2022, then surged 531.21% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at -$2000.0 in 2021, then sank by 35300.0% to -$708000.0 in 2022, then soared by 531.21% to $3.1 million in 2023, then sank by 138.72% to -$1.2 million in 2024, then soared by 86.72% to -$157000.0 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$157000.0, -$325000.0, and -$461000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 678,000.00 |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -157,000.00 |
| Sep 30, 2025 | -325,000.00 |
| Jun 30, 2025 | -461,000.00 |
| Mar 31, 2025 | -755,000.00 |
| Dec 31, 2024 | -1.18 Mn |
| Sep 30, 2024 | -1.71 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | -583,000.00 |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | -565,000.00 |
| Jun 30, 2023 | -29,000.00 |
| Mar 31, 2023 | -616,000.00 |
| Dec 31, 2022 | -708,000.00 |
| Sep 30, 2022 | -63,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -6,000.00 |
| Mar 31, 2021 | -5,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Dec 31, 2017 | 27,000.00 |